APAC Acute Myeloid Leukemia Treatment Market Size and Trends

The APAC acute myeloid leukemia (AML) treatment market size is forecast to increase by USD 305.8 million at a CAGR of 13.9% between 2023 and 2028. The market is witnessing significant growth due to the high incidence of this cancer type worldwide. According to the American Cancer Society, AML accounts for approximately one-third of all leukemia diagnoses. A key trend in the market is the adoption of Chimeric Antigen Receptor T-cell (CAR-T) therapy for AML treatment. This innovative approach, which involves engineering a patient's own T-cells to target and destroy cancer cells, has shown promising results in clinical trials. However, challenges remain, particularly in developing nations, where the lack of adequate healthcare infrastructure hampers the widespread adoption of advanced treatment modalities. Despite these challenges, the market is expected to grow steadily due to the increasing demand for effective AML treatments and ongoing research and development efforts.

 Request Free Sample

Acute Myeloid Leukemia (AML), a type of bone marrow cancer characterized by the production of abnormal myeloid cells, is a significant health concern worldwide. The rising prevalence of genetic mutations due to unhealthy lifestyles, hazardous chemicals, and radiation exposure are major factors driving the demand for advanced therapeutics in AML treatment. Traditional chemotherapy remains the primary treatment modality for AML, which involves induction chemotherapy through parenteral administration. However, the emergence of targeted therapies and novel approaches, such as Quizartinib, which specifically target specific genetic mutations, offers promising outcomes for high-risk AML patients. The market for AML treatment is expected to grow due to the increasing number of screening programs and the development of new therapies for Myeloblastic Leukemia and chromosomal abnormalities. Hospitals and clinics, along with specialty centers, are the primary end-users of these treatments. The immune system plays a crucial role in the treatment of AML, with ongoing research focusing on harnessing its potential through cancer immunotherapies. The market for AML treatment is expected to witness significant growth due to the increasing incidence of AML, advancements in technology, and the development of new therapies.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

• Type
  • Chemotherapy
  • Stem cell transplantation
  • Others
• Geography
  • APAC
    • China
    • India
    • Japan

By Type Insights

The chemotherapy segment is estimated to witness significant growth during the forecast period. Acute Myeloid Leukemia (AML), a type of cancer that affects the production of white blood cells in the bone marrow, can be caused by various factors including genetic mutations, unhealthy lifestyles, exposure to hazardous chemicals, and radiation. Advanced therapeutic options are being explored for high-risk AML patients, with a focus on targeted therapies and novel treatments such as Quizartinib.

Get a glance at the market share of various segment Download the PDF Sample

The chemotherapy segment was the largest segment and was valued at USD 123.60 million in 2018. Chemotherapy and immunotherapy continue to be the mainstay of AML treatment, administered through parenteral and oral medications. Home healthcare and health technology assessment are increasingly being utilized to improve patient outcomes. Precision medicine, an approach that tailors treatment to individual genetic makeup, is gaining traction in the field of AML. Clinical trials and drug approvals are paving the way for innovative therapies. Hence, such factors are fuelling the growth of this segment during the forecast period.

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

High incidence of acute myeloid leukemia is notably driving market growth. The rising incidence of Acute Myeloid Leukemia (AML) in the Asia-Pacific (APAC) region is fueling growth in the treatment market, driven by the need for effective therapeutic options against abnormal myeloid cells.

Advancements in pharmacology and molecular biology are leading to innovative therapies, such as targeted treatments and stem cell transplants, which are increasingly utilized in clinical practice. The APAC AML market is categorized into chemotherapy, targeted therapies, and stem cell transplantation. Chemotherapy, a primary approach for both induction and consolidation phases, remains essential. Targeted therapies, known for their effectiveness, are gaining popularity.  Thus, such factors are driving the growth of the market during the forecast period.

Significant Market Trends

CAR T-cell therapy for AML is the key trend in the market. Acute Myeloid Leukemia (AML), characterized by the production of abnormal myeloid cells, is a type of myeloblastic leukemia marked by chromosomal abnormalities. The primary treatment approaches for AML include induction chemotherapy administered through parenteral or oral means in hospitals and clinics, specialty centers, homecare settings, ambulatory care centers, and other healthcare facilities.

While induction chemotherapy effectively reduces the number of leukemia cells, it often results in significant mortality and morbidity due to damage to healthy cells. Recent advancements in cancer treatment have focused on Chimeric Antigen Receptor T-cell (CAR T-cell) therapy, which holds potential for AML treatment. However, challenges persist in applying this approach to AML, including the difficulty of identifying unique antigens on AML cells without affecting normal hematopoietic stem cells and the immunosuppressive tumor microenvironment, which hampers CAR T-cell efficacy. Thus, such trends will shape the growth of the market during the forecast period.

Major Market Challenge

Lack of adequate healthcare infrastructure in developing nations is the major challenge that affects the growth of the market. Acute Myeloid Leukemia (AML), also known as myeloblastic leukemia, is a type of cancer characterized by the production of abnormal myeloid cells in the bone marrow. Chromosomal abnormalities are commonly observed in AML patients, leading to uncontrolled cell growth and suppression of normal blood cell production.

Induction chemotherapy is the primary treatment approach for AML, which involves the administration of anticancer drugs through parenteral or oral routes. Hospitals and specialty centers, as well as ambulatory care centers and homecare settings, offer treatment for AML patients. However, the large-sized radiotherapy and chemotherapy devices require significant installation space, posing a challenge for underdeveloped and emerging economies with limited healthcare infrastructure and expenditure. Hence, the above factors will impede the growth of the market during the forecast period.

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

AbbVie Inc: The company offers AML treatment for blood cancer patients.

The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Agios Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• Astex Pharmaceuticals Inc.
• Bristol Myers Squibb Co.
• CTI BioPharma Corp.
• Cyclacel Pharmaceuticals, Inc.
• Daiichi Sankyo Co. Ltd.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Jazz Pharmaceuticals Plc
• Johnson and Johnson Services Inc.
• MEI Pharma Inc
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Analyst Overview

Acute Myeloid Leukemia (AML), a type of cancer that affects the production of white blood cells in the bone marrow, is a global health concern. The rising prevalence of genetic mutations, unhealthy lifestyles, exposure to hazardous chemicals, and radiation are key factors driving the demand for advanced therapeutics in AML treatment. AML patients, particularly those in the high-risk category, require innovative therapies such as targeted therapies and novel oral medications like Quizartinib. Chemotherapy and immunotherapy continue to be the mainstay of AML treatment, delivered via parenteral and oral routes. Homecare and health technology assessment are gaining popularity in AML treatment, enabling better patient care and reducing hospitalization. Precision medicine and clinical trials are paving the way for new drug approvals, focusing on specific genetic mutations and individual patient needs. The liver, spleen, central nervous system, lymph nodes, and testicles are common sites of AML spread. Sedentary lifestyles and poor screening programs contribute to the late diagnosis and poor prognosis of AML. Stem cell transplantation, myeloblastic therapy, and novel targeted therapies are under development to improve treatment outcomes. Health reimbursement and government initiatives are expected to boost the AML treatment market growth.

Download PDF Sample

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market  and its contribution of the market in focus to the parent market
• Accurate predictions about upcoming market growth and trends and changes in consumer behaviour
• Growth of the market across APAC
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch